Pharmacogenomic testing identifies gene polymorphisms impacting drug metabolism, aiding in optimizing treatment efficacy and minimizing toxicity, thus potentially reducing healthcare utilization. 6-mercaptopurine metabolism is affected by thiopurine methyltransferase (TPMT) and nudix hydrolase 15 (NUDT15) polymorphisms. We sought to estimate the budget impact of preemptive pharmacogenomic testing for these genes in pediatric acute lymphoblastic leukemia (ALL) patients from an institutional perspective. This is in response to heightened costs associated with supplemental care for adverse events, like severe myelosuppression, resulting from traditional dosing of 6-mercaptopurine.

EE320 Budget Impact Analysis of TPMT and NUDT15 Pharmacogenomic Testing for 6-Mercaptopurine in Pediatric Acute Lymphocytic Leukemia Patients